Vinod Balasubramaniam
Molecular Virologist and the Leader of the Infection and Immunity Research Strength from the Jeffrey Cheah School of Medicine & Health Sciences at Monash University in Malaysia
The WHO declaration is scientifically justified, but it should not be read as a reason for public panic. Ebola does not spread like COVID-19 or influenza. It usually requires direct contact with blood, body fluids, contaminated materials, or unsafe healthcare and burial practices. This means Ebola outbreaks can be controlled, but only if the response is early, coordinated and trusted by communities.
What makes this outbreak important is that it involves Bundibugyo virus, a rarer member of the ebolavirus family. Most of the vaccines and antibody treatments we commonly associate with Ebola were developed for Zaire ebolavirus, not Bundibugyo virus. At best, a Zaire-based vaccine may provide limited or partial cross-reactive immunity, but in practical outbreak control, we should not assume reliable protection unless this is proven. This is why a Bundibugyo-specific vaccine, or ideally a broader pan-ebolavirus vaccine, is likely needed.
The warning signs are clear. Suspected undetected transmission, spread across borders, and infections or deaths among healthcare workers. When healthcare workers are affected, the health system itself becomes vulnerable, and that can accelerate an outbreak.
The priorities now are straightforward. This includes rapid diagnosis, safe isolation, contact tracing, strong infection prevention in hospitals, safe and dignified burials, and honest communication with communities. For countries outside the affected region, including Australia and Southeast Asia, the immediate risk remains low, but preparedness still matters. This is not about border closures or fear. It is about supporting affected countries quickly and using evidence-based public health before the outbreak becomes harder to contain.